Citryll B.V.

Inflammatory Mediated Immune Diseases

Citryll B.V. focuses on inflammatory mediated immune diseases with studies aimed at understanding how its investigational program behaves in immune-driven conditions. This area reflects interest in immunology and the treatment of chronic inflammatory disorders.

  • Immune-mediated inflammation
  • Inflammatory disease activity
  • Translational imaging

The sponsor’s research activity in this area includes work spanning multiple countries and collaborating sites, supporting clinical evaluation in broad immune-inflammatory settings.

Hidradenitis Suppurativa

Another key area of interest is hidradenitis suppurativa, a chronic inflammatory skin disease marked by recurrent lesions and persistent disease burden. The sponsor is studying therapeutic effects in patients with moderate to severe disease.

  • Chronic skin inflammation
  • Disease burden in hidradenitis suppurativa
  • Clinical response in dermatologic inflammation

This therapeutic focus places dermatology and immune-mediated skin disorders at the center of the company’s clinical research portfolio.

Rheumatoid Arthritis

Citryll B.V. is also active in rheumatoid arthritis, with research centered on patients with moderately active disease. This area highlights interest in autoimmune joint disease and persistent synovial inflammation.

  • Autoimmune arthritis
  • Joint inflammation
  • Rheumatology

The sponsor’s work in this field aligns with clinical investigation of therapies intended for chronic musculoskeletal inflammation and disease control.

Diagnostic and Imaging-Oriented Clinical Research

One part of the sponsor’s research landscape involves PET-based imaging and the evaluation of radiolabeled investigational compounds in immune-mediated conditions. This indicates therapeutic interest in both treatment assessment and biological distribution within inflammatory disease settings.

  • Positron emission tomography
  • Radiolabeled compounds
  • Target engagement in inflammatory disease

These activities connect molecular imaging with the clinical study of autoimmune and inflammatory disorders.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • Evaluation of CIT-013 at two dose levels compared to placebo for treating moderate to severe Hidradenitis Suppurativa

    Recruiting

    2 1
    Germany The Netherlands Poland Spain
  • Study Using PET Imaging to See How [89Zr]Zr-DFO-CIT-013 Spreads in Patients with Inflammatory Mediated Immune Diseases

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands
  • Study of CIT-013 at Three Different Doses for Patients with Moderately Active Rheumatoid Arthritis

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Germany The Netherlands Poland Spain